Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493539 | 1.00 | EGFR (0.83) | EGFRERBB2 | |
| SCHEMBL5496959 | 0.94 | EGFR (0.86) | EGFRERBB2 | |
| SCHEMBL5496956 | 0.94 | EGFR (0.86) | EGFRERBB2 | |
| SCHEMBL5499792 | 0.92 | EGFR (0.85) | EGFRERBB2 | |
| SCHEMBL5499786 | 0.92 | EGFR (0.85) | EGFRERBB2 | |
| SCHEMBL22847992 | 0.92 | EGFR (0.85) | EGFRERBB2 | |
| SCHEMBL4964726 | 0.91 | EGFR (0.84) | EGFRERBB2 | |
| SCHEMBL5989738 | 0.91 | EGFR (0.84) | EGFRERBB2 | |
| SCHEMBL2204366 | 0.91 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL2204372 | 0.91 | EGFR (1.00) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448531-B1 | 3-CYANOQUINOLINES AS INHIBITORS OF EGF-R AND HER2 KINASES | WYETH CORP (US) | 2007-08-15 | — | — | EP | disclosed |
| US-6821988-B2 | FOR USE AS ANTINEOPLASTIC AGENTS AND IN THERAPY OF POLYCYSTIC KIDNEY DISEASE | WYETH HOLDINGS CORPORATION | 2004-11-23 | — | — | US | disclosed |
| EP-1448531-A1 | 3-CYANOQUINOLINES AS INHIBITORS OF EGF-R AND HER2 KINASES | Wyeth Holdings Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030149056-A1 | 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases | AMERICAN CYANAMID COMPANY | 2003-08-07 | — | — | US | disclosed |
| WO-2003050090-A1 | 3-CYANOQUINOLINES AS INHIBITORS OF EGF-R AND HER2 KINASES | WYETH HOLDINGS CORPORATION (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149056-A1 | 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.